Comparative Effectiveness Hits Medical Devices
Converging provider, payor and regulatory forces are making comparative effectiveness and evidence of value top priority issues for device companies. This article was excerpted from the March 2010 issue of In Vivo.
You may also be interested in...
As the FDA revamps the medical device approval process, significant overhauls are expected for both the PMA and 510(k) pathways. Medtech Insight is presenting a series of articles focusing on the effect these changes will have to the industry, starting with this first installment focused on potential changes to premarket approvals.
Manufacturers of UK personal care products watch out, the Competition and Markets Authority is on the look-out for false, exaggerated and/or vague sustainability claims, and may be targeting bigger players to make an example for the rest of the sector. And consumer health might be next. HBW Insight returns to advice from marketing expert Jo Stephenson on how to avoid greenwashing, based on the CMA's own extensive Green Claims Code.
One outcome of last year’s public consultation on UK MHRA fees is a hefty uplift in charges payable by medtech manufacturers in 2023, beyond which the agency is keen to pursue a new fees and charges plan.